Vsevolod V Gurevich1, Eugenia V Gurevich2. 1. Department of Pharmacology, Vanderbilt University, Nashville, TN, United States. Electronic address: vsevolod.gurevich@vanderbilt.edu. 2. Department of Pharmacology, Vanderbilt University, Nashville, TN, United States.
Abstract
Arrestins play a key role in homologous desensitization of G protein-coupled receptors (GPCRs) and regulate several other vital signaling pathways in cells. Considering the critical roles of these proteins in cellular signaling, surprisingly few disease-causing mutations in human arrestins were described. Most of these are loss-of-function mutations of visual arrestin-1 that cause excessive rhodopsin signaling and hence night blindness. Only one dominant arrestin-1 mutation was discovered so far. It reduces the thermal stability of the protein, which likely results in photoreceptor death via unfolded protein response. In case of the two nonvisual arrestins, only polymorphisms were described, some of which appear to be associated with neurological disorders and altered response to certain treatments. Structure-function studies revealed several ways of enhancing arrestins' ability to quench GPCR signaling. These enhanced arrestins have potential as tools for gene therapy of disorders associated with excessive signaling of mutant GPCRs.
n class="Gene">Arrestins play a key role in homologous desensitization of G protein-coupled receptors (GPCRs) and regulate several other vital signaling pathways in cells. Considering the critical roles of these proteins in cellular signaling, surprisingly few disease-causing mutations in humanarrestins were described. Most of these are loss-of-function mutations of visual arrestin-1 that cause excessive rhodopsin signaling and hence night blindness. Only one dominant arrestin-1 mutation was discovered so far. It reduces the thermal stability of the protein, which likely results in photoreceptor death via unfolded protein response. In case of the two nonvisual arrestins, only polymorphisms were described, some of which appear to be associated with neurological disorders and altered response to certain treatments. Structure-function studies revealed several ways of enhancing arrestins' ability to quench GPCR signaling. These enhanced arrestins have potential as tools for gene therapy of disorders associated with excessive signaling of mutant GPCRs.
Authors: K Saidas Nair; Susan M Hanson; Matthew J Kennedy; James B Hurley; Vsevolod V Gurevich; Vladlen Z Slepak Journal: J Biol Chem Date: 2004-07-21 Impact factor: 5.157
Authors: M Ikeda; N Ozaki; T Suzuki; T Kitajima; Y Yamanouchi; Y Kinoshita; T Kishi; Y Sekine; M Iyo; M Harano; T Komiyama; M Yamada; I Sora; H Ujike; T Inada; N Iwata Journal: Genes Brain Behav Date: 2007-02 Impact factor: 3.449
Authors: L M Luttrell; S S Ferguson; Y Daaka; W E Miller; S Maudsley; G J Della Rocca; F Lin; H Kawakatsu; K Owada; D K Luttrell; M G Caron; R J Lefkowitz Journal: Science Date: 1999-01-29 Impact factor: 47.728
Authors: Stephen J Perry; George S Baillie; Trudy A Kohout; Ian McPhee; Maria M Magiera; Kok Long Ang; William E Miller; Alison J McLean; Marco Conti; Miles D Houslay; Robert J Lefkowitz Journal: Science Date: 2002-10-25 Impact factor: 47.728
Authors: Henrike Indrischek; Sonja J Prohaska; Vsevolod V Gurevich; Eugenia V Gurevich; Peter F Stadler Journal: BMC Evol Biol Date: 2017-07-06 Impact factor: 3.260